
From: Kristin Kuciapinski <Kristin.Kuciapinski@ParatekPharma.com>
Sent: Tuesday, January 22, 2019 4:24 PM
To: AGO - High Cost Prescription Drugs
Subject: New Prescription Drug Manufacturer Report - Manufacturer: Paratek Pharmaceuticals, Inc.

To Whom It May Concern:

Paratek Pharmaceuticals, Inc. would like to notify you, pursuant to 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs), that our new product, NUZYRA™ (omadacycline) will be commercially available as of February 1, 2019.

NUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with Community-acquired bacterial pneumonia (CABP) or acute bacterial skin and skin structure infections (ABSSI), caused by susceptible micro-organisms.

Below please find all key product information regarding NUZYRA.

Brand Name	Generic Name	Therapeutic Category	Strength	Dosage Form
NUZYRA	omadacycline	antibacterial	100 mg	VIAL (EA)
NUZYRA	omadacycline	antibacterial	150 mg	TABLET
NUZYRA	omadacycline	antibacterial	150 mg	TABLET
NUZYRA	omadacycline	antibacterial	150 mg	TABLET

Access to the NUZYRA product insert can be found at:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209816_209817lbl.pdf

If you have any questions, please feel free to contact me directly at the number below.

Sincerely,

Kristin Kuciapinski

Senior Manager, Trade Relations

Kristin.Kuciapinski@Paratekpharma.com

O: 484.751.4974

Paratek Pharmaceuticals | www.Paratekpharma.com

1000 First Ave, Suite 200, King of Prussia, PA 19406

